Drug interaction refers to the compound effect produced by the patient taking two or more drugs at the same time or within a certain period of time, which can enhance the drug effect and reduce the side effects, or reduce the drug effect and cause additional side effects.

According to the principle of occurrence, it can be divided into pharmacokinetics and pharmacodynamic interactions.

  • Pharmacodynamics

The pharmacodynamic interaction is that a drug changes the sensitivity or response of the tissue to another drug through the same (competitive) or blocking (antagonistic) effect.

  • Pharmacokinetics

The pharmacokinetic interaction is usually that one drug changes the absorption, distribution, protein binding, metabolism, or excretion of another drug, thereby changing the number and duration of the drug available at the receptor site.

Project Process

Solutions for You

Creative Bioarray is a professional service provider for drug preclinical research and provides a series of in vitro drug-drug interaction assays. We design and implement drug-drug interaction studies to provide customers with accurate and reliable data for follow-up research. Our approach complies with regulatory guidelines. Our comprehensive plan includes:

  • Many metabolic pathways can be inhibited or induced by combined drugs. The main drug-metabolizing enzymes related to metabolism-based drug-drug interactions are cytochrome P450 (CYP450). According to current statistics, more than 90% of clinically metabolic drug interactions are caused by changes in CYP450 enzyme activity. In terms of mechanism, metabolism-based drug-drug interactions can be divided into enzyme inhibition and enzyme induction.
  • CYP450 reaction phenotyping Identification

    CYP450 inhibition

    CYP450 induction

  • Uridine diphosphate glucuronic acid transferase (UGT) is an important phase II metabolism enzyme in the human body. UGT enzymes are the key enzymes for inactivating and removing endogenous substances. Interaction towards UGTs is under attention by regulatory authorities, especially when one of the major elimination pathways of the investigational drug is direct glucuronidation.

UGT reaction phenotyping identification

UGT inhibition

UGT induction

  • Certain compounds are not metabolized by CYP or UGT enzymes, but can be metabolized by other enzymes, such as monooxygenase (FMO), monoamine oxidase (MAO), N-acetyltransferase (NAT), aldehyde oxidase (AOX), carboxylesterase (CE). These enzymes can also be inhibited by drugs, leading to drug interactions.

Inhibition towards other metabolizing enzymes

Transporter interactions

PXR and AhR nuclear receptor activation

Project Process

Creative Bioarray focuses on creating a one-stop service, dedicated to saving time and cost for customers, improving communication efficiency and accelerating the process of new drug research and development. Our drug interaction research uses mature technologies to provide a reliable basis for new drug development and drug preclinical research.

Project Process

Why Choose Us

Professional Platform and Excellent Team

We have a professional technical platform, equipped with advanced instruments and talented and well-trained experts.

Committed to Quality

We put quality first. We provide high-quality products, services and solutions to support customers worldwide.

World-class Service Capabilities

We provide one-stop service, from order to final report, to provide the best solution for your research. We hope to help you complete your research more easily and efficiently.


We adhere to a mutually beneficial and win-win cooperation model, pay attention to customer needs and goals, and create the greatest value for customers.

If you are interested in our services, please contact us for more detailed information.

* For scientific research only

Online Inquiry